Skip to main content

Table 2 Patient information for predominant histological subtypes in all cases

From: The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010

  Total Group A
(AIS + MIA)
Group B
(Lepidic)
Group C
(Papillary + acinar
 + variant)
Group D
(Solid + micropapillary)
p-value
n 2863 304 526 1745 287  
Sex (male/Female), n (%) 1478/1385 (51.6%) 119/185 (39.1%) 233/293 (44.3%) 940/805
(53.8%)
185/102
(64.4%)
 < 0.001
Age, mean ± SD 66.71 ± 9.15 66.49 ± 9.67 67.72 ± 8.20 66.46 ± 9.23 65.88 ± 9.38 0.025
Smoking history ( ±), n (%) 1471 / 1308 (52.9%) 110/187
(37.0%)
222 / 292 (43.2%) 741 / 594 (55.5%) 205 / 72
(74.0%)
 < 0.001
Operation time (min.), mean ± SD 205.25 ± 66.89 203.47 ± 62.70 198.60 ± 66.50 207.41 ± 67.76 204.13 ± 66.12 0.017
Invasion, n (%)
   Lymph vessel invasion ( ±), n (%) 777 / 1785 (30.3%) 0 / 273
(0%)
76 / 412 (15.6%) 565 / 978 (36.6%) 131 / 130 (50.2%)  < 0.001
   Vascular invasion ( ±), n (%) 695 / 1875 (27.3%) 0 / 278
(0%)
49 / 440
(10.0%)
494 / 1059
(31.8%)
152 / 111
(57.8%)
 < 0.001
  Pleural invasion ( ±), n (%) 691 / 2156 (24.3%) 0 / 316 (0%) 63/ 461 (12.1%) 517 / 1224
(29.7%)
111 / 174
(38.9%)
 < 0.001
 EGFR mutation ( ±) 641 / 783 (45.0%) 72 / 54 (57.1%) 118 / 96 (55.1%) 426 / 522
(44.9%)
33 / 122 (21.3%)  < 0.001
 Adjuvant therapy ( ±) 1017 / 1820 (35.8%) 17 / 287 (5.9%) 152 / 368 (29.2%) 697 / 1034
(40.3%)
143 / 140 (50.5%)  < 0.001
 Clinical stage
IA / IB / IIA / IIB / IIIA
1732 / 749 / 190 / 83 / 98 272 / 31 / 1 / 0 / 0 316 / 171 / 22 / 9 / 8 1015 / 462 / 132 / 59 / 77 143 / 82 / 32 / 11 / 19  < 0.001
 Pathological stage
IA / IB / IIA / IIB / IIIA
1426 / 732 / 260 / 110 / 314 298 / 6 / 0 / 0 / 0 319 / 150 / 18 / 7 / 32 749 / 493 / 195 / 75 / 233 82 / 68 / 50 / 23 / 64  < 0.001